Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Abatacept in Patients With Primary Sjogren's Syndrome
Phase of Trial: Phase III
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Abatacept (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms ASAPIII
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 18 Mar 2019 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019.